M J Landray

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. pmc Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
    Richard Haynes
    Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Headington Oxford OX3 7LF, UK
    Transplant Res 2:7. 2013
  2. ncbi request reprint Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment
    M J Landray
    Division of Medical Sciences, University of Birmingham, UK
    Am J Kidney Dis 38:537-46. 2001
  3. pmc Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study
    Martin J Landray
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
    Am J Kidney Dis 56:1082-94. 2010
  4. ncbi request reprint Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study
    Martin J Landray
    Clinical Trial Service Unit, University of Oxford, Oxford, UK
    Am J Kidney Dis 43:244-53. 2004
  5. ncbi request reprint The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD
    Martin Landray
    Clinical Trial Service Unit, University of Oxford, Churchill Hospital, Oxford, UK
    Am J Kidney Dis 47:385-95. 2006
  6. doi request reprint Commentary: Controversies in NICE guidance on chronic kidney disease
    Martin J Landray
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF
    BMJ 337:a1793. 2008
  7. pmc Abnormalities of endothelial function in patients with predialysis renal failure
    J Thambyrajah
    Division of Medical Sciences Cardiology, University of Birmingham, Birmingham B15 2TH, UK
    Heart 83:205-9. 2000
  8. doi request reprint Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men
    J R Emberson
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
    J Intern Med 268:145-54. 2010
  9. ncbi request reprint The cardioprotective role of beta-blockers in patients with diabetes mellitus
    M J Landray
    Division of Medical Sciences, University of Birmingham, Birmingham, UK
    J Clin Pharm Ther 27:233-42. 2002
  10. ncbi request reprint Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
    Semin Dial 20:498-503. 2007

Detail Information

Publications12

  1. pmc Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
    Richard Haynes
    Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Headington Oxford OX3 7LF, UK
    Transplant Res 2:7. 2013
    ..CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely. However, the safety and efficacy of such strategies are unknown...
  2. ncbi request reprint Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment
    M J Landray
    Division of Medical Sciences, University of Birmingham, UK
    Am J Kidney Dis 38:537-46. 2001
    ..These results will be further quantified in a prospective biennial follow-up...
  3. pmc Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study
    Martin J Landray
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
    Am J Kidney Dis 56:1082-94. 2010
    ..Validated prediction scores are required to assess the risks of end-stage renal disease (ESRD) and death in individuals with chronic kidney disease (CKD)...
  4. ncbi request reprint Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study
    Martin J Landray
    Clinical Trial Service Unit, University of Oxford, Oxford, UK
    Am J Kidney Dis 43:244-53. 2004
    ..Studies in the general population suggest that low-grade inflammation, endothelial dysfunction, and platelet activation are associated with an increased risk of cardiovascular events...
  5. ncbi request reprint The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD
    Martin Landray
    Clinical Trial Service Unit, University of Oxford, Churchill Hospital, Oxford, UK
    Am J Kidney Dis 47:385-95. 2006
    ..In preparation for such a trial, we assessed the biochemical efficacy, safety, and tolerability of adding ezetimibe, 10 mg/d, to simvastatin, 20 mg/d, as initial therapy for such patients...
  6. doi request reprint Commentary: Controversies in NICE guidance on chronic kidney disease
    Martin J Landray
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF
    BMJ 337:a1793. 2008
  7. pmc Abnormalities of endothelial function in patients with predialysis renal failure
    J Thambyrajah
    Division of Medical Sciences Cardiology, University of Birmingham, Birmingham B15 2TH, UK
    Heart 83:205-9. 2000
    ..Endothelial dysfunction plays an important role in the development of atherosclerotic vascular disease, which is the leading cause of mortality in patients with chronic renal failure...
  8. doi request reprint Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men
    J R Emberson
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
    J Intern Med 268:145-54. 2010
    ..To assess the relevance of cystatin C, as a marker of mild-to-moderate renal impairment, for vascular and nonvascular mortality in older people...
  9. ncbi request reprint The cardioprotective role of beta-blockers in patients with diabetes mellitus
    M J Landray
    Division of Medical Sciences, University of Birmingham, Birmingham, UK
    J Clin Pharm Ther 27:233-42. 2002
    ..Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded...
  10. ncbi request reprint Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
    Semin Dial 20:498-503. 2007
    ....
  11. ncbi request reprint Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study
    Daniel Zehnder
    Department of Nephrology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK
    Nephron Clin Pract 107:c109-16. 2007
    ..However, it is unclear at what stage of chronic kidney disease (CKD) these abnormalities develop...
  12. ncbi request reprint A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots
    Marion M Mafham
    Renal Studies Group, Clinical Trial Service Unit, Old Road Campus, Oxford, UK
    Nephron Clin Pract 106:c104-12. 2007
    ..Exogenous tracer-based methods of measuring glomerular filtration rate (GFR) are difficult to perform, whilst creatinine-based estimation formulae are inaccurate...